세계의 전자 약물전달 시스템 시장 규모 : 유형별, 적응증별, 지역 범위별 및 예측

Electronic Drug Delivery Systems Market Size And Forecast

Electronic Drug Delivery Systems Market size was valued at USD 10.57 Billion in 2024 and is projected to reach USD 19.26 Billion by 2032, growing at a CAGR of 7.79% from 2026 to 2032.

The high prevalence of various chronic disorders and increase in the geriatric patient pool susceptible to cardiovascular and respiratory diseases are the major drivers that propelled the market's demand in the forecast period. The Global Electronic Drug Delivery Systems Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Electronic Drug Delivery Systems Market Definition

These are electronically enabled, smart drug delivery devices are well suited to home care settings. These devices add value to traditional instruments and improve ease of administration, convenience, and portability. However, these systems offer valuable advantages within hospitals and other clinical settings. Electronic drug delivery systems rapidly manage chronic ailments, including diabetes, cardiovascular diseases, respiratory disorders, and other applications.

Nowadays, different technologies are being merged with computation tools to innovate drug delivery systems such as electronic drug delivery systems. It offers several benefits to patients, which include medical professionals, caregivers, and drug regimens. Wearable infusion pumps, injectable insulin pens, electronic autoinjectors, and electronic inhalers are some of the electronic drug delivery systems available in the market. Timely and appropriate insulin dosing are critical concerns in diabetes patients, and electronic insulin pens can help patients.

Global Electronic Drug Delivery Systems Market Overview

The market's significant factors include the increasing prevalence of chronic diseases, such as diabetes, asthma, cardiovascular disease, and technological advancements in developing smart drug delivery systems. Several advantages such as improved efficiency, lesser time consumption, minimum side effects, and self-administered therapy for patients offered by electronic drug delivery systems over conventional drug delivery methods are expected to boost the market's growth globally. Electronic drug delivery systems ensure whether the medications are correctly delivered to the patient's body or not. It helps remind the patients about their drugs intake routine and provides appropriate guidance on using their medications.

Approvals of novel drug formulations in infusion pumps allow a novel treatment option, advancing diabetes care in adults. Moreover, the smart wearable infusion pumps allow the patients to connect to smartphone apps wirelessly. This enables healthcare professionals to track patient data and tailor specific therapies as per individual requirements. The launch of connected autoinjectors for the management of diabetes is expected to drive market growth. Autoinjectors and electronic pumps are the primary devices used in chronic diseases to deliver smaller doses. The factors mentioned above have augmented the demand for electronic drug delivery systems globally.

However, the high cost of systems, the need for maintenance, the availability of alternative modes of drug delivery, and lack of awareness in low-income countries will restrict the global Electronic Drug Delivery Systems Market. In addition, automated pumps may have risks of the wrong dosage with technical glitches and might lead to adverse drug reactions. This may hinder the market growth. Technological advancements allow accessible self-administration technologies, mainly in infusion pumps and autoinjectors that help in large-volume and high-viscosity biologic drugs, which have created a potential market opportunity for the companies.

Global Electronic Drug Delivery Systems Market: Segmentation Analysis

The Global Electronic Drug Delivery Systems Market is Segmented on the basis of Type, Indication, and Geography.

Electronic Drug Delivery Systems Market, By Type

• Wearable Infusion Pumps
• Autoinjectors
• Injection Pens
• Inhalers

Based on Type, the market is bifurcated into wearable infusion pumps, autoinjectors, injection pens, and inhalers. Wearable infusion pumps hold the largest market share. The segment will retain its dominant position throughout the forecast period as these pumps are widely used for diabetes management. The injection pen segment is likely to register the fastest CAGR. The approval for injection pens to treat diabetes, offering a portable and convenient option, is expected to increase the segment's market share over the forecast period.

Electronic Drug Delivery Systems Market, By Indication

• Diabetes
• Multiple Sclerosis
• Cardiovascular Disease
• Others

Based on Indication, the market is bifurcated into diabetes, multiple sclerosis, cardiovascular disease, and others. The diabetes segment dominates the market due to the high prevalence rate of diabetes among other chronic diseases worldwide and rising adoption of smartphone apps, easy availability of devices like insulin pumps and injection pens by major market players by market players compared to other electronic drug delivery systems.

Electronic Drug Delivery Systems Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of regional analysis, the Global Electronic Drug Delivery Systems Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The largest share in the market will be dominated by North America. The increased incidence of target diseases, a rise in the patient population, favorable remuneration policies, and the launch of advanced Electronic Drug Delivery Systems by significant players are attributed to the increase in market revenue.

Key Players

The "Global Electronic Drug Delivery Systems Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Gerresheimer AG, Amgen, Novo Nordisk, Bayer AG, Medtronic plc, Insulet Corporation, AstraZeneca, Tandem Diabetes Care, Merck Group, and United Therapeutics Corporation.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ELECTRONIC DRUG DELIVERY SYSTEMS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL ELECTRONIC DRUG DELIVERY SYSTEMS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porter Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL ELECTRONIC DRUG DELIVERY SYSTEMS MARKET, BY TYPE

• 5.1 Overview
• 5.2 Wearable Infusion Pumps
• 5.3 Autoinjectors
• 5.4 Injection Pens
• 5.5 Inhalers

6 GLOBAL ELECTRONIC DRUG DELIVERY SYSTEMS MARKET, BY INDICATION

• 6.1 Overview
• 6.2 Diabetes
• 6.3 Multiple Sclerosis
• 6.4 Cardiovascular Disease
• 6.5 Others

7 GLOBAL ELECTRONIC DRUG DELIVERY SYSTEMS MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Middle East and Africa
  • 7.5.2 Latin America

8 GLOBAL ELECTRONIC DRUG DELIVERY SYSTEMS MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Gerresheimer AG
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Amgen
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Novo Nordisk
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Bayer AG
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Medtronic plc
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Insulet Corporation
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 AstraZeneca
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Tandem Diabetes Care
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Merck Group
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 United Therapeutics Corporation
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 Appendix

• 10.1 Related Research